EE447 Cost Implications of Adverse Event Profiles in Second Generation Androgen Receptor Inhibitor (SGARI) Treatments for Non-Metastatic Castration Resistant Prostate Cancer (NMCRPC)

J Chou,E Bell,I Brewer,S Appukkuttan,J Partridge,Sx Kong,R Maclean

doi:10.1016/j.jval.2022.04.695

EE447 Cost Implications of Adverse Event Profiles in Second Generation Androgen Receptor Inhibitor (SGARI) Treatments for Non-Metastatic Castration Resistant Prostate Cancer (NMCRPC)

J Chou, E Bell + Show 5 more

Open Access

https://doi.org/10.1016/j.jval.2022.04.695

Copy DOI

Journal: Value in Health	Publication Date: Jun 25, 2022
License type: publisher-specific-oa

Affiliation: D-Tree International, Bayer (United States)

#Second Generation Androgen Receptor Inhibitor #Non-metastatic Castration Resistant Prostate Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

EE447 Cost Implications of Adverse Event Profiles in Second Generation Androgen Receptor Inhibitor (SGARI) Treatments for Non-Metastatic Castration Resistant Prostate Cancer (NMCRPC)

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Value in Health

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.